Our target identification analysis also nominated ITGB2 as another unappreciated target in endometriosis pathology, which has been implicated in multiple immune functions.[37, 65, 66, 67] The clinically approved drug Lifitegrast, which potently inhibits ITGB2 function, was proposed for treating endometriosis. Here, ITGB2 is linked to endometriosis.